Jordan: Hikma signs licensing agreement to bring innovative oncology treatment to MENA
AMMAN — Hikma Pharmaceuticals PLC (Hikma) on Wednesday announced an exclusive licensing agreement with pharmaand GmbH (pharma&), a global pharmaceutical company based in Vienna, Austria.
The agreement grants Hikma exclusive rights to commercialise rucaparib across the Middle East and North Africa (MENA) region, the Jordan New Agency, Petra, reported.
Rucaparib, marketed as Rubraca, is an innovative small-molecule oral therapy designed to inhibit poly (ADP-ribose) polymerases (PARPs), a family of proteins critical to DNA repair in cancer cells.
This mechanism makes rucaparib an 'important' treatment option for patients battling ovarian cancer, the eighth most common cancer in women globally, and prostate cancer, the fourth most common cancer worldwide and the second most common cancer in men.
Rucaparib has received regulatory approval from the European Medicines Agency (EMA) and the United States Food and Drug Administration (USFDA).
Hikma Executive Vice Chairperson and President of MENA Mazen Darwazah said: "We are pleased to add rucaparib, an innovative oncology treatment, to our growing oncology portfolio in MENA.'
'This agreement is a major step to further enhance patients' access to life-changing treatments and address critical medical needs across the region. By strengthening our oncology portfolio, we reaffirm our commitment to providing advanced cancer treatments and supporting our purpose of putting better health within reach, every day,' Darwazah added.
As the company's first innovative small-molecule oral therapy in oncology approved by the USFDA and EMA, this partnership boosts Hikma's promise of providing better access to life saving treatment options and its commitment to improving patient outcomes, he noted.
© Copyright The Jordan Times. All rights reserved. Provided by SyndiGate Media Inc. (Syndigate.info).
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Web Release
24-04-2025
- Web Release
Hikma reiterates full year guidance following good start to the year
Hikma Pharmaceuticals PLC (Hikma, Group), the multinational pharmaceutical group, today provides an update on current trading ahead of its Annual General Meeting. Riad Mishlawi, Hikma's CEO, said: 'We are pleased to reiterate our Group guidance for 2025. As a global company with strong local expertise and footprint, we are leveraging our manufacturing proficiency and advanced technologies to meet the needs of our customers and patients across our markets. Looking ahead, and recognising the broader geo-political challenges, we are well-positioned. Our step up in R&D investment, alongside local manufacturing enhancements, and strategic partnerships will continue to strengthen our portfolio and pipeline and ensure sustained success.' Injectables Our global Injectables business is delivering a solid revenue performance, driven by each of our three geographies. We are seeing strong demand for our products across our European and MENA markets, where we continue to launch new products. In North America we are benefitting from good demand for the recently launched liraglutide injection and the contribution from the newly acquired Xellia portfolio. This is helping to offset increased competition across some of our existing higher margin products. We expect momentum to improve in the second half driven by new product launches and contract manufacturing. We are making excellent progress in the enhancements to our Bedford, Ohio facility, which will significantly increase our US-based injectables manufacturing capacity. We continue to expect 2025 Injectables revenue to grow in the range of 7% to 9%. Phasing and mix of sales will impact margins in the first half but we continue to expect full year core operating margin to be in the mid-30s. Branded Our Branded business is performing well. We continue to make good progress in building our diversified portfolio of products used to treat chronic illnesses, with a focus on oncology and lifestyle diseases, supported by our global expertise and strong local market position. Our leading presence in the MENA region, combined with the breadth of our reach and strong commercial capabilities positions us as a partner of choice. We recently signed an exclusive licensing agreement with pharmaand GmbH, a global pharmaceutical business based in Vienna, to commercialise rucaparib, an innovative small-molecule oral oncology therapy, across the MENA region. This is in line with our strategy to be a leading provider of oncology medicines in the region. We continue to expect 2025 Branded revenue to grow in the range of 6% to 7% in constant currency, with core EBIT margin close to 25%. Generics In our Generics business we are seeing solid demand across our differentiated portfolio, particularly for our nasal and inhalation products. By focusing on reliability of supply, high service levels and leveraging our US manufacturing facility, we are successfully securing longer-term customer awards. We continue to strengthen our R&D capabilities, including building a team in our new Zagreb, Croatia R&D centre, and are progressing with key development projects that will help strengthen our portfolio and pipeline for the medium to long-term. We are progressing well preparing our Columbus facility to accommodate our recently announced contract manufacturing partnership, and we are seeing increasing demand for our high-quality US-based manufacturing services. We continue to expect Generics revenue to be broadly flat in 2025 with core operating margin of around 16%. International trade policies We are confident that our significant and expanding US manufacturing footprint, which supplies the majority of our US sales, combined with our focus on quality and reliability of supply, positions us well and underpins our resilience in the current environment. We do import some finished products into the US as well as capital equipment, and we have a diversified global supply chain for our raw and packaging materials, including active pharmaceutical ingredients (API). Full year outlook unchanged We continue to expect Group revenue to grow in the range of 4% to 6% and for core operating profit to be in the range of $730 million to $770 million in 2025. Group core operating profit growth, which is around 4% at the midpoint of guidance, will be weighted to the second half. We are monitoring the evolving tariff backdrop and will look to remain agile in responding to both opportunities and impacts where possible, but have not reflected an impact from tariffs in our full year outlook.
Zawya
24-04-2025
- Zawya
Hikma reiterates full year guidance following good start to the year
Amman, Jordan: Hikma Pharmaceuticals PLC (Hikma, Group), the multinational pharmaceutical group, today provides an update on current trading ahead of its Annual General Meeting. Riad Mishlawi, Hikma's CEO, said: 'We are pleased to reiterate our Group guidance for 2025. As a global company with strong local expertise and footprint, we are leveraging our manufacturing proficiency and advanced technologies to meet the needs of our customers and patients across our markets. Looking ahead, and recognising the broader geo-political challenges, we are well-positioned. Our step up in R&D investment, alongside local manufacturing enhancements, and strategic partnerships will continue to strengthen our portfolio and pipeline and ensure sustained success." Injectables Our global Injectables business is delivering a solid revenue performance, driven by each of our three geographies. We are seeing strong demand for our products across our European and MENA markets, where we continue to launch new products. In North America we are benefitting from good demand for the recently launched liraglutide injection and the contribution from the newly acquired Xellia portfolio. This is helping to offset increased competition across some of our existing higher margin products. We expect momentum to improve in the second half driven by new product launches and contract manufacturing. We are making excellent progress in the enhancements to our Bedford, Ohio facility, which will significantly increase our US-based injectables manufacturing capacity. We continue to expect 2025 Injectables revenue to grow in the range of 7% to 9%. Phasing and mix of sales will impact margins in the first half but we continue to expect full year core operating margin to be in the mid-30s. Branded Our Branded business is performing well. We continue to make good progress in building our diversified portfolio of products used to treat chronic illnesses, with a focus on oncology and lifestyle diseases, supported by our global expertise and strong local market position. Our leading presence in the MENA region, combined with the breadth of our reach and strong commercial capabilities positions us as a partner of choice. We recently signed an exclusive licensing agreement with pharmaand GmbH, a global pharmaceutical business based in Vienna, to commercialise rucaparib, an innovative small-molecule oral oncology therapy, across the MENA region. This is in line with our strategy to be a leading provider of oncology medicines in the region. We continue to expect 2025 Branded revenue to grow in the range of 6% to 7% in constant currency, with core EBIT margin close to 25%. Generics In our Generics business we are seeing solid demand across our differentiated portfolio, particularly for our nasal and inhalation products. By focusing on reliability of supply, high service levels and leveraging our US manufacturing facility, we are successfully securing longer-term customer awards. We continue to strengthen our R&D capabilities, including building a team in our new Zagreb, Croatia R&D centre, and are progressing with key development projects that will help strengthen our portfolio and pipeline for the medium to long-term. We are progressing well preparing our Columbus facility to accommodate our recently announced contract manufacturing partnership, and we are seeing increasing demand for our high-quality US-based manufacturing services. We continue to expect Generics revenue to be broadly flat in 2025 with core operating margin of around 16%. International trade policies We are confident that our significant and expanding US manufacturing footprint, which supplies the majority of our US sales, combined with our focus on quality and reliability of supply, positions us well and underpins our resilience in the current environment. We do import some finished products into the US as well as capital equipment, and we have a diversified global supply chain for our raw and packaging materials, including active pharmaceutical ingredients (API). Full year outlook unchanged We continue to expect Group revenue to grow in the range of 4% to 6% and for core operating profit to be in the range of $730 million to $770 million in 2025. Group core operating profit growth, which is around 4% at the midpoint of guidance, will be weighted to the second half. We are monitoring the evolving tariff backdrop and will look to remain agile in responding to both opportunities and impacts where possible, but have not reflected an impact from tariffs in our full year outlook. About Hikma Hikma helps put better health within reach every day for millions of people around the world. For more than 45 years, we've been creating high-quality medicines and making them accessible to the people who need them. Headquartered in the UK, we are a global company with a local presence across North America, the MENA and Europe, and we use our unique insight and expertise to transform cutting-edge science into innovative solutions that transform people's lives. We're committed to our customers, and the people they care for, and by thinking creatively and acting practically, we provide them with a broad range of branded and non-branded generic medicines. Together, our 9,500 colleagues are helping to shape a healthier world that enriches all our communities. We are a leading licensing partner, and through our venture capital arm, are helping bring innovative health technologies to people around the world. For more information, please visit: *Source: AETOSWire
Web Release
12-04-2025
- Web Release
Ministry of Economy licenses Emirati Musicians' Association to safeguard the rights of creators and musicians enhancing competitiveness of UAE's creative economy
The Ministry of Economy announced the granting of the Collective Music Management license to the Emirati Musicians' Association (EMA), as part of its efforts to organize the collection and distribution of rights of music creators and ensure that media channels and content streaming platforms uphold copyrights held by creators in the UAE's music industry. The initiative contributes to enhancing the competitiveness of the UAE's creative economy and supports the establishment of a sustainable creative environment in line with global best practices, fostering the growth of talent and innovators. The Ministry explained that the issuance of the license is in alignment with the Federal Decree-Law No. 38 of 2021 on copyright and neighboring rights. The ceremony was organized by the Ministry in Abu Dhabi, in collaboration with the International Federation of Phonographic Industry (IFPI) and the International Confederation of Societies of Authors and Composers (CISAC). It was attended by H.E. Abdullah Ahmed Al Saleh, Undersecretary of the Ministry of Economy, who delivered the keynote address, along with H.E. Mubarak Al Nakhi, Undersecretary of the Ministry of Culture, and H.E. Dr. Abdulrahman Hassan Al Muaini, Assistant Undersecretary for the Intellectual Property (IP) Sector at the Ministry of Economy. The event was also attended by representatives of various music sector entities, composers, artists, producers, various international organizations specializing in copyright protection, in addition to experts and stakeholders from the music industry and the UAE's IP protection landscape. H.E. Abdulla bin Touq Al Marri, Minister of Economy, emphasized that the UAE has successfully created an advanced legislative environment aligned with global best practices to strengthen IP protection. This enhances the competitiveness of the cultural and creative sectors, which are key drivers of the national economy. Over the past years, the UAE has successfully developed an integrated ecosystem for protecting authors' rights by updating legislation and launching impactful initiatives that keep pace with digital transformation and modern innovations, as reflected in the Copyright and Neighboring Rights Law. These developments have accelerated the country's efforts to position the creative economy as a fundamental pillar of sustainable economic growth. H.E. Bin Touq added: 'The licensing of EMA marks a significant milestone in our efforts to enhance the growth of creative economy in the UAE, as it is one of the key pillars of the 'We the UAE 2031' vision. We aspire to make our country a regional and global hub for culture, talent, and creative content through the development of an attractive and stimulating legislative and regulatory framework.' The Minister of Economy explained that the initiative is the latest step in building an institutional framework that protects rights, enhances justice, and creates new opportunities for artists, authors, and producers within the UAE. This will contribute to the development of the creative industries related to music. It is also part of the continuing efforts to achieve the objectives of the Cultural and Creative Industries Strategy, aimed at building a supportive environment that protects the rights of creators, attracting investment in the music sector, and establishing clear and transparent mechanisms for the collection and distribution of revenues. Furthermore, H.E. pointed out that the licensing aims to create a strong and competitive collective management ecosystem for the music sector, which is key to attracting investment in the cultural industries and enabling partnerships between the public and private sectors. The Ministry of Economy does not limit its role to granting licenses, and will continue to provide technical and legislative support, as well as enhance cooperation with the Association to carry out its assigned tasks in accordance with best global practices. H.E. added: 'The Ministry of Economy, in cooperation with relevant authorities from the public and private sectors, continues its efforts to provide all possible means to protect intellectual property rights across all economic sectors in the country, especially in creative industries. These sectors have witnessed remarkable growth in recent years, in light of the country's abundant capabilities and opportunities for creators and innovators in various sectors and activities related to intellectual property and creativity.' His Excellency Sheikh Salem bin Khalid Al Qassimi, Minister of Culture, affirmed that the granting of the first license to practice collective management of music rights consolidates the UAE's position as a leading destination in the field of intellectual property and a supporter of the music industry, which is a vital part of the creative economy. He pointed out that collective management is key to stimulating innovation, protecting the rights of creators, and building a sustainable environment that balances the interests of authors and artists with market requirements. His Excellency said: 'The launch of this license represents a pivotal milestone in our cultural journey and reflects our vision for a future where creativity thrives. We at the Ministry of Culture are committed to empowering this sector through quality initiatives, most notably the National Grant Program for Culture and Creativity, which provides comprehensive support to Emirati creatives, with the aim of enhancing cultural production and developing cultural and creative industries.' His Excellency added: 'The move contributes to creating a sustainable environment that supports artists and authors, preserves their original work and moral rights, and ensures the continuity of creative production, enhancing the confidence of talented individuals that their creations are protected by fair laws that encourage innovation.' The Ministry of Economy explained that it will work in cooperation with EMA to develop an advanced digital platform that enables the registration of rights and promotes efficiency in revenue management, in addition to organizing awareness workshops for artists to apprise them of their rights and the mechanisms for protecting them. Cooperation with international institutions working in the field of copyright will also be enhanced, leveraging global experiences in implementing the best legal and technical practices in this field. Gadi Oron, Director General of the International Confederation of Societies of Authors and Composers (CISAC), said: 'I am delighted to be attending this ceremony, which marks the awarding of the license to the Emirati Musicians' Association. This is a significant step that will certainly serve as a model for other entities. At CISAC, we are proud to have been part of a unique international collaboration to achieve this milestone, and we will continue our commitment to supporting the development of EMA and helping it become a successful organization that represents creators both within the country and globally.' Victoria Oakley, CEO of the International Federation of the Phonographic Industry (IFPI), stated: 'The Emirati Musicians' Association has a governance system that meets international standards for managing public performance and broadcasting rights. The licensing of the association by the Ministry of Economy is another step towards establishing the UAE as one of the most vibrant and exciting music markets in the world. This is especially true given that the IFPI Global Music Report 2024 showed that this region is the fastest-growing music recording market globally. IFPI is proud to support these efforts and wishes it continued success and progress.' The UAE prioritizes the development of an environment conducive to the growth and prosperity of creative industries. It has developed a number of laws and policies aimed at increasing the creative economy's contribution to national economic growth. This has boosted the contribution of cultural and creative industries to the UAE's GDP in 2022, up 3.5 per cent, equivalent to AED 54.4 billion. In 2024, the global music industry saw its revenues grow by 4.8 per cent, reaching $29.6 billion, according to a report by IFPI. The Middle East and North Africa region grew by 22.8 per cent to become the fastest-growing recorded music market globally.
